X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES JUBILANT LIFE SCIENCES VENUS REMEDIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -896.4 23.9 - View Chart
P/BV x 0.3 4.9 5.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 VENUS REMEDIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
VENUS REMEDIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs218187 116.7%   
Low Rs8265 126.1%   
Sales per share (Unadj.) Rs365.6364.3 100.3%  
Earnings per share (Unadj.) Rs1.56.8 21.7%  
Cash flow per share (Unadj.) Rs37.924.5 154.8%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs382.5164.9 232.0%  
Shares outstanding (eoy) m11.44159.28 7.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.40.3 118.7%   
Avg P/E ratio x101.018.4 548.8%  
P/CF ratio (eoy) x4.05.1 77.0%  
Price / Book Value ratio x0.40.8 51.4%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m1,71720,061 8.6%   
No. of employees `0001.06.2 16.5%   
Total wages/salary Rs m32411,052 2.9%   
Avg. sales/employee Rs Th4,100.79,383.0 43.7%   
Avg. wages/employee Rs Th318.01,786.9 17.8%   
Avg. net profit/employee Rs Th16.7176.3 9.5%   
INCOME DATA
Net Sales Rs m4,18358,034 7.2%  
Other income Rs m20191 10.5%   
Total revenues Rs m4,20358,224 7.2%   
Gross profit Rs m8125,786 14.0%  
Depreciation Rs m4172,812 14.8%   
Interest Rs m3803,237 11.7%   
Profit before tax Rs m35-72 -48.7%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m18696 2.6%   
Profit after tax Rs m171,090 1.6%  
Gross profit margin %19.410.0 194.6%  
Effective tax rate %51.6-965.9 -5.3%   
Net profit margin %0.41.9 21.6%  
BALANCE SHEET DATA
Current assets Rs m2,77129,280 9.5%   
Current liabilities Rs m1,93138,912 5.0%   
Net working cap to sales %20.1-16.6 -120.9%  
Current ratio x1.40.8 190.6%  
Inventory Days Days12584 148.2%  
Debtors Days Days5451 106.0%  
Net fixed assets Rs m5,32855,712 9.6%   
Share capital Rs m114155 74.0%   
"Free" reserves Rs m4,17720,968 19.9%   
Net worth Rs m4,37626,265 16.7%   
Long term debt Rs m1,91117,169 11.1%   
Total assets Rs m8,42888,606 9.5%  
Interest coverage x1.11.0 111.7%   
Debt to equity ratio x0.40.7 66.8%  
Sales to assets ratio x0.50.7 75.8%   
Return on assets %4.74.9 96.4%  
Return on equity %0.44.2 9.4%  
Return on capital %6.611.6 57.1%  
Exports to sales %037.8 0.0%   
Imports to sales %20.516.5 124.5%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs m8589,567 9.0%   
Fx inflow Rs m022,004 0.0%   
Fx outflow Rs m85811,749 7.3%   
Net fx Rs m-85810,255 -8.4%   
CASH FLOW
From Operations Rs m4698,026 5.8%  
From Investments Rs m29-1,744 -1.7%  
From Financial Activity Rs m-464-4,447 10.4%  
Net Cashflow Rs m351,834 1.9%  

Share Holding

Indian Promoters % 32.9 45.6 72.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 0.2 8.7 2.1%  
FIIs % 0.6 21.2 2.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 21.1 314.7%  
Shareholders   20,121 23,815 84.5%  
Pledged promoter(s) holding % 36.4 15.9 229.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   NOVARTIS  TORRENT PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS